Grants and Contributions:
Title:
Medicago Proposal to fill Canada's pandemic preparedness gap
Agreement Number:
815733
Agreement Value:
$169,872,474.00
Agreement Date:
Oct 17, 2020 - Apr 1, 2043
Description:
The Project was planned to be undertaken in two stages to (1) develop a plant-derived virus-like particle (VLP) vaccine for the prevention of COVID-19; and (2) establish a large-scale GMP Facility for vaccine and antibody production in Canada.
Organization:
Innovation, Science and Economic Development Canada
Expected Results:
The company had planned to secure up to 76 million doses of Medicago’s COVID-19 vaccine candidate, enough to vaccinate 38 million people. Medicago had committed to creating 75 jobs and maintaining 275 over the term.
Location:
Quebec, Quebec, CA G1V3V9
Reference Number:
033-2020-2021-Q3-815733
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
872308499
Recipient Type:
For-profit organization
Additional Information:
The amendment has been completed to terminate by mutual consent Medicago’s contribution agreement.
Amendment Date
Nov 24, 2023
Recipient's Operating Name:
Medicago inc.
Recipient's Legal Name:
Medicago inc.
Federal Riding Name:
Louis-Hébert
Federal Riding Number:
24044
Program:
SIF Stream3- Attraction
Program Purpose:
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
NAICS Code:
541710
Amendments: